REG - Kromek Group PLC - Notice of AGM and Publication of Annual Report

KromekAnnouncement

02/09/2022 17:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220902:nRSB1767Ya&default-theme=true

RNS Number : 1767Y  Kromek Group PLC  02 September 2022

2 September 2022

 

Kromek Group plc

("Kromek" or the "Group")

 

Notice of AGM and Publication of Annual Report

 

Kromek Group plc, a leading developer of radiation and bio-detection
technology solutions for the advanced imaging and CBRN detection segments,
gives notice that its Annual General Meeting ("AGM") will be held at 9.30am on
28 September 2022 at The Coxon Building, North East Technology Park (NETPark),
John Walker Road, Sedgefield, County Durham, TS21 3FE.

 

The notice of AGM and form of proxy, along with the Group's annual report and
accounts for the year ended 30 April 2022, have today been posted to those
shareholders who have requested paper communications. These documents are also
available on the Investor Relations section of the Group's website at
https://www.kromek.com/investor-relations/
(https://protect-eu.mimecast.com/s/HuRhCBnpQTljoGIzJb_r) and can be accessed
by clicking on the "AGM 2022" page.

 

 

For further information, please contact:

 

 Kromek Group plc
 Arnab Basu, CEO                                                 +44 (0)1740 626 060

 Paul Farquhar, CFO

 finnCap Ltd (Nominated Adviser and Broker)
 Geoff Nash/Seamus Fricker/George Dollemore - Corporate Finance  +44 (0)20 7220 0500
 Tim Redfern/Charlotte Sutcliffe - ECM

 Gracechurch Group (Financial PR)
 Harry Chathli/Claire Norbury                                    +44 (0)20 3488 7510

 

 

About Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments. Headquartered in County Durham, UK, Kromek has manufacturing
operations in the UK and US, delivering on the vision of enhancing the quality
of life through innovative detection technology solutions.

 

The advanced imaging segment comprises the medical (including CT and SPECT),
security and industrial markets. Kromek provides its OEM customers with
detector components, based on its core cadmium zinc telluride (CZT) platform,
to enable better detection of diseases such as cancer and Alzheimer's,
contamination in industrial manufacture and explosives in aviation
settings.

 

In CBRN detection, the Group provides nuclear radiation detection solutions to
the global homeland defence and security market. Kromek's compact, handheld,
high-performance radiation detectors, based on advanced scintillation
technology, are primarily used to protect critical infrastructure and urban
environments from the threat of 'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN detection
segment. These consist of fully automated and autonomous systems to detect a
wide range of airborne pathogens.

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the
trading symbol 'KMK'.

 

Further information is available at www.kromek.com (http://www.kromek.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOABKBBBABKDQCK